Aktiesnakken — December 2011
-
-
TOPO: "In xenografted mice, PXD101 in combination with irinotecan dramatically inhibited tumor growth without causing additive toxicity." http://www.ncbi.nlm.nih.gov/pubmed/21046105
-
den er jo så illikvid at der ikke skal meget til, desværre
-
TOPO: CONCLUSION
"Belinostat acts as an efficient anti-tumor agent both alone and in combination with other chemotherapeutic agents. As it is non-toxic and shows specific action it proved to be an efficient anti-tumor agent." http://www.articlesbase.com/medicine-articles/belinostat-pxd101-an-efficient-inhibitor-of-hdacs-5475550.html
-
hej gorm, prækliniske data er altid gode
-
det tager 15 år før det er omsat i et lægemiddel der tjener penge
-
spansk obl auktion gik ok http://www.forexlive.com/blog/2011/12/15/spanish-auction-results-6/
-
selvfølgelig er vejen en smule lettere i andre indikationer, men kun lidt. du skal stadig igennem 3 faser af forsøg i hver indikation. Bare tænk Genmab og NHL!
-
off label kan man ikke regne med som investor og det ligger stadig temmeligt langt ude i fremtiden
-
den spa 10årige er også netop faldet fra ca 5,7% til 5,55%
-
det vigtigste i biotek investeringer er at forstå risici, herunder de fundamentale forhold i virksomheden og dernæst hvilke kliniske data der har betydning for euforien og hvilke der rent faktisk betyder noget for indtjeningen (typisk milestones)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind